secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2022-09-13T23:59:59+00:00
Accession:  0001104659-22-099487
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise announces FDA authorization for Phase 2 DMD trial; positive ARCH interim data in BMD
--------------------------------------------------------------------------------

- FDA authorized Phase 2 LYNX trial of EDG-5506 in children with DMD; dosing expected Q4 2022.
- ARCH interim data: NSAA improved 1.17 points vs natural history decline of 1.22/year.
- CK reduced 29% and fast skeletal muscle troponin I reduced 74% after 4 months.
- 9 of 12 BMD participants showed improvement or no decline on NSAA; no serious AEs observed.
- EDG-5506 well-tolerated with no discontinuations; all patients dose escalated to 20 mg daily.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465922099487/0001104659-22-099487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465922099487/tm2221772d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-099487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer